Search Results

Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners (“Arsenal”), announced today the acquisition of Mosaic Laboratories LLC (“Mosaic”), a California-based company offering histology and immunohistochemistry services to global pharmaceutical clients

Caprion-HistoGeneX, a leading global contract research laboratory services provider backed by Arsenal Capital Partners, announced today the acquisition of Clinical Logistics Inc. (“CLI”), a Virtual Central Specimen Management CRO based in Halifax, Canada . The acquisition enables Caprion-HistoGeneX to broaden its specimen logist

Caprion-HistoGeneX offers COVID-19 PCR testing services in partnership with Clinical Logistics, a virtual central laboratory for a complete and worry-free service from sample collection to easy-to-interpret reports.

Caprion-HistoGeneX and Viroclinics-DDL announced today a new strategic partnership to expand their global capabilities addressing the emerging needs for therapeutic and prophylactic solutions to target infectious diseases including COVID-19.

Today in Nature Medicine, researchers from Barts Cancer Institute (London), Queen Mary University of London together with pathologists from HistoGeneX (Belgium), a laboratory focused on tissue pathology and genomics, published findings that may significantly alter the treatment of bladder cancer

Partnership Facilitated by Major Investment from Arsenal Capital Partners

In this landmark study, a follow-up to BluePrint 1, a global team of thoracic pathologists reviewed the immunostains of five clinical grade PD-L1 IHC assays (22C3, 28-8, SP142, SP263, and 73-10).

The McGill University Health Centre Foundation and MEDTEQ+ are proud to announce a new partnership with the Research Institute of the McGill University Health Centre, MIMs, and Caprion-HistoGeneX, respective leaders in cancer research, artificial intelligence, and precision medicine, to increase survival of stage IV colorectal cancer patients.

Led by Dr. Virginia Litwin, Vice-President of Flow Cytometry, will include pharmaceutical, biotech and regulatory leaders in biomarker research.

Arsenal Capital Partners (“Arsenal”), a leading specialized private equity firm investing in specialty industrials and healthcare companies, announced today the addition of Michael Bernstein to its healthcare team.